Merck, Ridgeback: Molnupiravir Associated With More Rapid Elimination of Infectious SARS-CoV-2

 Additional Exploratory Patient Subgroup and Virology Data from MOVe-OUT Presented at ECCMID

Among Patients With Infectious Virus at Baseline, No Patients Who Received LAGEVRIO Had Infectious Virus at Days 3, 5 or 10

https://finance.yahoo.com/news/merck-ridgeback-present-data-demonstrating-104000870.html